Page last updated: 2024-10-28

hydroxychloroquine and alpha 1-Antitrypsin Deficiency

hydroxychloroquine has been researched along with alpha 1-Antitrypsin Deficiency in 1 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

alpha 1-Antitrypsin Deficiency: Deficiency of the protease inhibitor ALPHA 1-ANTITRYPSIN that manifests primarily as PULMONARY EMPHYSEMA and LIVER CIRRHOSIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Cruz, MA1
Bohinc, D1
Andraska, EA1
Alvikas, J1
Raghunathan, S1
Masters, NA1
van Kleef, ND1
Bane, KL1
Hart, K1
Medrow, K1
Sun, M1
Liu, H1
Haldeman, S1
Banerjee, A1
Lessieur, EM1
Hageman, K1
Gandhi, A1
de la Fuente, M1
Nieman, MT1
Kern, TS1
Maas, C1
de Maat, S1
Neeves, KB1
Neal, MD1
Sen Gupta, A1
Stavrou, EX1

Other Studies

1 other study available for hydroxychloroquine and alpha 1-Antitrypsin Deficiency

ArticleYear
Nanomedicine platform for targeting activated neutrophils and neutrophil-platelet complexes using an α
    Nature nanotechnology, 2022, Volume: 17, Issue:9

    Topics: alpha 1-Antitrypsin Deficiency; Animals; Humans; Hydroxychloroquine; Leukocyte Elastase; Mice; Nanom

2022